Synergistic combination of immunologic inhibitors for the treatment of cancer
AssigneeThe University of Chicago
InventorsThomas F. Gajewski, Stefani Spranger, Michael Leung
Life of this patent
Estimating the term…
Abstract
In some embodiments, the methods involve the use of a combination of at least two of the following: an inhibitor of indoleamine-2,3-dioxygenase (IDO), an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an inhibitor of CD25, or IL-7. The inventors particularly observed a major synergistic effect of combining anti-CTLA-4 with either an IDO inhibitor, with anti-PD-L1 mAb, or with CD-25 depletion. Such combinations have been found to demonstrate a synergistic effect in treating cancer and tumors, for example by reducing tumor size, increasing the percentage of antigen-specific T cells, and increasing T cell function.
Claims25
A method of treating cancer in a subject comprising administering to the subject an effective amount of at least two of the following:
- an inhibitor of indoleamine-2,3-dioxygenase (IDO), an inhibitor of the PD-L1/PD-1 pathway, or an inhibitor of CTLA-4.
3-4. (canceled)
7-9. (canceled)
12-14. (canceled)
22-34. (canceled)
42-46. (canceled)
Dependencies are inferred from the claim text.